REFERENCES
- Froland S S. Bacterial infections in the compremised host. Scand J Infect Dis. 1984; 43: 7–16, [CSA]
- Klastersky J. Empiric treatment of infection during granulocytopenia: a comprehensive approach. Infection. 1989; 17: 59–94, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pizzo P A, Commers J, Cotton D, et al. Approaching the controversies in the antibacterial management of cancer patients. Am J Med. 1984; 76: 436, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Leoni F, Ciolli S, Pascarella A, Fanci R, Caporale R, Rossi Ferrini P. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients. Chemotherapy. 1993; 39: 147–152, [PUBMED], [INFOTRIEVE], [CSA]
- Pizzo P A, Hathorn J W, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552–558, [PUBMED], [INFOTRIEVE], [CSA]
- Chastagner P, Plouvier E, Eyer D, Plesiat P, Lozniewski A, Sommelet D. Efficacy of cefepime and amikacin in the empiric treatment of febrile neutropenic children with cancer. Med Pediatr Oncol. 2000; 34: 306–308, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hughes W T, Armstrong D, Bodey G P, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin J Infect Dis 1997; 25: 551–573, [CSA]
- Bodey G P. Evolution of antibiotic therapy for infection in neutropenic patients: studies at M.D. Anderson Hospital. Rev Infect Dis 1989; 11: S1582–S1590, [PUBMED], [INFOTRIEVE], [CSA]
- Wang F D, Liu C Y, Hsu H C, et al. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients. Chemotherapy 1999; 45: 370–379, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Raad I I, Escalante C, Hachem R Y, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003; 98: 1039–1047, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jandula B M, Martino R, Gurgi M, Manteiga R, Sierra J. Treatment of febrile neutropenia with cefepime monotherapy. Chemotherapy. 2001; 47: 226–231, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Edwards J R. Meropenem: a microbiological overview. J Antimicrob Chemother 1995; 36(Suppl A)1–17, [PUBMED], [INFOTRIEVE], [CSA]
- Wiseman L R, Wagstaff A J, Brogden R N, Bryson H M. Meropenem: a review of its antibacterial activity, pharmokinetic properties and clinical efficacy. Drugs. 1995; 50: 73–101, [PUBMED], [INFOTRIEVE], [CSA]
- Sanders C C. Cefepime the next generation?. Clin Infect Dis. 1993; 17: 369–379, [PUBMED], [INFOTRIEVE], [CSA]
- Thornsberry C, Brown S D, Yee Y C, Bouchillon S K, Marler J K, Rich T. In-vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother 1993; 32(Suppl B)31–53, [PUBMED], [INFOTRIEVE], [CSA]
- Mustafa M M, Carlson L, Tkaczewski I, McCracken G H, Jr, Buchanan G R. Comperative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2001; 20: 362–369, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lindblad R, Rodjer S, Adriansson M, et al. Empiric monotherapy for febrile neutropenia: a randomized study comparing meropenem with ceftazidime. Scand J Infect Dis 1998; 30: 237–243, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kutluk T, Kurne O, Akyuz C, et al. Cefepime vs meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours. Pediatr Blood Cancer 2004; 42: 284–286, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bucaneve G, Menichetti F, Minotti V, Pasticci M B, Tonato M, Del Favero A. Ceftriaxone versus imipenem/cilastatin as empirical monotherapy for infections in cancer patients. Chemotherapy 1989; 35(Suppl 2)10–15, [PUBMED], [INFOTRIEVE], [CSA]
- Eggimann P, Glauser M P, Aoun M, Meunier F, Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother 1993; 32(Suppl B)31–53, [CSA]
- Hughes W T, Armstrong D, Bodey G P, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002; 34: 730–751, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Borbolla J R, Lopez-Hernandez M A, Gonzalez-Avante M, et al. Comparison cefepime versus ceftriaxone–amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients. Chemotherapy 2001; 47: 381–384, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996; 100: 83S–89S, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C I. Open randomized study of cefepime versus piperacillin-gentamicin for the treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother. 1997; 41: 1704–1708, [PUBMED], [INFOTRIEVE], [CSA]
- Bohme A, Shah P M, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res. 1998; 3: 324–330, [PUBMED], [INFOTRIEVE], [CSA]
- Kebudi R, Gorgun O, Ayan I, Gurler N, Akici F, Toreci K. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pediatr Oncol. 2001; 36: 434–441, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M, the IATCG of EORTC. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br J Haematol 1997; 99: 580–588, [PUBMED], [CROSSREF], [CSA]